Testing version — LOERadar is in active testing. Features and data may change.
PAXIL CR (PAROXETINE HYDROCHLORIDE) | LOERadar
PAXIL CR
NDA
PAROXETINE HYDROCHLORIDE | N020936 | APOTEX INC
3 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
#001 — EQ 12.5MG BASE
RLDAB
0 patents0 exclusivities▴
TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 16, 1999
No patent or exclusivity listings for this strength.
#002 — EQ 25MG BASE
RLDAB
0 patents0 exclusivities▾
TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 16, 1999
#003 — EQ 37.5MG BASE
RLDAB
0 patents0 exclusivities▾
TABLET, EXTENDED RELEASE;ORAL | Approved: Dec 6, 2000